Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Elevated HbA1c = CVD
The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.
Read More »Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
Read More »The Positives and Negatives for Continuous Glucose Monitoring in Young Children
CGM use in young children with type 1 diabetes has its benefits and challenges, according to their parents.
Read More »The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Dulaglutide Provides CVD Protection with or without Metformin
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.
Read More »Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Care of the elderly can be very challenging. Can adding yet another medication actually help?
Read More »The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors
Is the risk as substantial as was initially reported?
Read More »